Cotización Imunon - IMNN

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

0.8699

Postura de Compra

0.86

Postura de Venta

0.87

Volume Operado de la Acción

3,511,153

0.81 Rango del Día 0.8855

0.48 Rango de 52 semanas 3.65

Capitalización de Mercado [m]

12.614M

Precio Anterior

0.8305

Precio de Apertura

0.85

Hora

0.8699

Última hora de negociación

Volumen financiero

US$ 2,966,861

Precio Promedio Ponderado

0.844982

Volumen promedio (3 m)

186,983

Acciones en circulación

14,500,685

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.63

Beneficio por acción (BPA)

-1.35

turnover

Beneficio neto

-19.52M

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to gen... Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Health Care Diversified

Sitio web

www.imunon.com

Sede

Dover, Delaware, USA

Fundado

1982

Imunon Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNN. The last closing price for Imunon was US$0.83. Over the last year, Imunon shares have traded in a share price range of US$ 0.48 to US$ 3.65.

Imunon currently has 14,500,685 shares in issue. The market capitalisation of Imunon is US$12.04 million. Imunon has a price to earnings ratio (PE ratio) of -0.63.

Form 4 - Statement of changes in beneficial ownership of securities

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable...

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian...

Form 8-K - Current report

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.0099	1.1511627907	0.86	1.27	0.8025	110981	0.84890513	CS
4	0.2064	31.1077618689	0.6635	1.27	0.64	192861	0.83817394	CS
12	-0.1401	-13.8712871287	1.01	1.27	0.64	186983	0.88635263	CS
26	-0.1801	-17.1523809524	1.05	3.65	0.64	1578619	2.68162981	CS
52	-0.0401	-4.40659340659	0.91	3.65	0.48	863286	2.56171068	CS
156	-1.0901	-55.6173469388	1.96	3.65	0.48	406305	2.49552602	CS
260	-1.0901	-55.6173469388	1.96	3.65	0.48	406305	2.49552602	CS

IMNN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Imunon?

El precio actual de las acciones de Imunon es US$ 0.8699

¿Cuántas acciones de Imunon están en circulación?

Imunon tiene 14,500,685 acciones en circulación

¿Cuál es la capitalización de mercado de Imunon?

La capitalización de mercado de Imunon es USD 12.04M

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Imunon?

Imunon ha negociado en un rango de US$ 0.48 a US$ 3.65 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Imunon?

El ratio precio/beneficio de Imunon es -0.63

¿Cuál es la moneda de reporte de Imunon?

Imunon presenta sus resultados financieros en USD

¿Cuál es el último beneficio anual de Imunon?

El último beneficio anual de Imunon es USD -19.52M

¿Cuál es la dirección registrada de Imunon?

La dirección registrada de Imunon es 874 WALKER RD STE C, KENT, DOVER, DELAWARE, 19904

¿Cuál es la dirección del sitio web de Imunon?

La dirección del sitio web de Imunon es www.imunon.com

¿En qué sector industrial opera Imunon?

Imunon opera en el sector HEALTH CARE DIVERSIFIED

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
PRFXPainReform Ltd	US$ 11.08 (410.60%)	95.4M
NVNINVNI Group Ltd	US$ 2.66 (315.63%)	20.64M
BPTHBio Path Holdings Inc	US$ 1.50 (124.22%)	113.42M
ZCARZoomcar Holdings Inc	US$ 2.5999 (96.96%)	18.03M
APCXAppTech Payments Corporation	US$ 0.6203 (62.81%)	196.08M
LITMSnow Lake Resources Ltd	US$ 0.3025 (-63.09%)	72.24M
BSFCBlue Star Foods Corporation	US$ 0.1478 (-48.14%)	7.45M
QUBTQuantum Computing Inc	US$ 15.1396 (-41.05%)	122.47M
QMCOQuantum Corporation	US$ 36.02 (-39.99%)	7.07M
AEMDAethlon Medical Inc	US$ 0.4232 (-35.94%)	9.52M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.561 (53.78%)	725.16M
NVDANVIDIA Corporation	US$ 130.68 (1.37%)	209.74M
APCXAppTech Payments Corporation	US$ 0.6203 (62.81%)	196.08M
RGTIRigetti Computing Inc	US$ 7.465 (-30.17%)	176.12M
SOUNSoundHound AI Inc	US$ 18.855 (-9.55%)	139.39M